GLENMARK \u2014 Recent Activity

Glenmark Pharmaceuticals Ltd (BOM:532296) Q3 2026 Earnings Call Highlights: Strong Revenue ...

Glenmark Pharmaceuticals Ltd (BOM:532296) reports a 15.1% YoY revenue increase, driven by robust India formulation sales and strategic product launches.

Click to open →

Cosmo Pharmaceuticals (SWX:COPN) Is Up 46.9% After Expanding Its Clascoterone Dermatology Franchise

Cosmo Pharmaceuticals recently reported successful Phase III results for its Clascoterone 5% solution in male hair loss and secured European Commission marketing authorization, via its partner Glenmark Pharmaceuticals, for Winlevi (clascoterone 10 mg/g cream) to treat acne vulgaris across 17 countries. Together, these milestones suggest Cosmo is extending the reach of its clascoterone franchise across two large dermatology indications, potentially reinforcing its position as an...

Click to open →

Glenmark Pharmaceuticals Ltd (BOM:532296) Q2 2026 Earnings Call Highlights: Robust Revenue ...

Glenmark Pharmaceuticals Ltd (BOM:532296) reports a 76% YoY revenue surge, driven by strong North America sales and strategic global expansion.

Click to open →

India's Glenmark posts higher quarterly profit on strong demand in N.America, Europe

(Reuters) -India's Glenmark Pharmaceuticals reported a 72% jump in second-quarter adjusted profit on Friday, on recovery in key North American and European markets.

Click to open →

China's Jiangsu Hengrui to grant license for cancer drug to unit of India's Glenmark

(Reuters) -China's Jiangsu Hengrui Pharmaceuticals said on Wednesday it has agreed to grant a paid license for its innovative cancer drug trastuzumab rezetecan to the Swiss unit of India's Glenmark

Click to open →

India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal

(Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie for its early-stage blood cancer treatment. The stock was the top percentage gainer on the Nifty Pharma index, which traded 0.3% higher compared to a 0.8% loss in the benchmark Nifty 50. Ichnos Glenmark Innovation (IGI) will receive an upfront payment of $700 million and could earn up to $1.22 billion in additional milestone payments.

Click to open →

Tesla robotaxi, AbbVie licenses Glenmark cancer drug, McDonald's

Yahoo Finance anchor Julie Hyman examines some of the top headlines on Wall Street on Thursday, July 10 in this episode of Market Minute. Tesla (TSLA) CEO Elon Musk says the company plans to expand its robotaxi rollout to San Francisco in the coming months. Glenmark (GLENMARK.NS, GLENMARK.BO) is set to license its cancer drug to AbbVie (ABBV), sending shares of both companies higher. McDonald's (MCD) was upgraded to Buy from Neutral by Goldman Sachs analysts, saying the fast-food restaurant is w

Click to open →

India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact

(Reuters) -India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have signed an exclusive licensing agreement for IGI's cancer treatment, adding to the U.S. firm's oncology portfolio. Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize IGI's ISB 2001 in North America, Europe, Japan and Greater China.

Click to open →

AbbVie to pay $700M for trispecific drug from Ichnos Glenmark

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and autoimmune conditions, too.

Click to open →

Glenmark Pharmaceuticals Ltd (BOM:532296) Q4 2025 Earnings Call Highlights: Strong FY25 Revenue ...

Glenmark Pharmaceuticals Ltd (BOM:532296) reports a robust 12.8% revenue growth for FY25, driven by European expansion and consumer care success, despite North American setbacks.

Click to open →